Mika Health and Cancer Support Community Aim to Close Gaps in Mental Health Care with United States' First AI-Enabled "Precision Support" Digital Therapeutic That is Free for Cancer Patients tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - .
SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and.